CELL INTELLIGENCE · 肿瘤细胞治疗研究

Lifileucel is a tumor-derived autologous T cell therapy approved for unresectable or metastatic melanoma in adults. This article discusses 10 clinical studies on lifileucel for the treatment of advanced melanoma. The phase II study data available evaluated the safety and efficacy of lifileucel in a global, multicenter study involving adult patients with unresectable or metastatic melanoma who had previously received systemic therapies, including a PD-1 blocking antibody and, if applicable, BRAF and MEK inhibitors. Among 73 patients treated with the recommended dose, the objective response rate was 31.5%, with 4.1% achieving a complete response and 27.4% a partial response. Of the responders, 56.5%, 47.8%, and 43.5% maintained their responses without progression or death at 6, 9, and 12 months, respectively. The most common adverse events seen in clinical studies include thrombocytopenia, anemia, and febrile neutropenia. Additional studies are underway to provide further data on the use of lifileucel as a safe and effective intravenous treatment option for unresectable or metastatic melanoma. This article reviews the published data encompassing the preliminary development, pharmacology, efficacy, and safety of lifileucel.